HIV-1 Vaccines and Adaptive Trial Designs-Reference-Cited by-同舟云学术

HIV-1 Vaccines and Adaptive Trial Designs

Published:2011-04-20 Issue:79 Volume:3 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Corey Lawrence¹²³,Nabel Gary J.⁴³,Dieffenbach Carl⁵,Gilbert Peter¹,Haynes Barton F.⁶,Johnston Margaret⁵,Kublin James¹,Lane H. Clifford⁷,Pantaleo Giuseppe⁸,Picker Louis J.⁹,Fauci Anthony S.¹⁰

Affiliation:

1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

2. Department of Medicine, University of Washington, Seattle, WA 98109, USA.

3. These authors contributed equally to this work.

4. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

5. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

6. Duke Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.

7. Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

8. Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University of Lausanne, CH-1015, Lausanne, Switzerland, and Swiss Vaccine Research Institute, 1011 Lausanne, Switzerland.

9. Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR 97205, USA.

10. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

Abstract

Development of an HIV vaccine could be accelerated by testing candidate vaccines using adaptive clinical trial designs.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference14 articles.

1. Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection

2. Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV‐1 Infection in a Phase 3 HIV‐1 Preventive Vaccine Trial

3. HIV‐1 Virologic and Immunologic Progression and Initiation of Antiretroviral Therapy among HIV‐1–Infected Subjects in a Trial of the Efficacy of Recombinant Glycoprotein 120 Vaccine

4. Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand

5. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2 Clinical Research on Infectious Diseases: An Overview;Principles and Practice of Emergency Research Response;2024

2. Randomized test-treatment studies with an outlook on adaptive designs;BMC Medical Research Methodology;2021-06-01

3. Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions;Frontiers in Immunology;2020-10-28

4. The complex challenges of HIV vaccine development require renewed and expanded global commitment;The Lancet;2020-02

5. Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions;The Lancet HIV;2019-05